Not yet recruiting
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
NCT07933419· Phase 1/2· Qilu Pharmaceutical Co., Ltd.· Source
Contact: Jinming Yu, PhD
Recruiting
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
NCT07798947· Phase 2· Shanghai Hengrui Pharmaceutical Co., Ltd.· Source
Contact: Jinming Yu
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
NCT07640789· Phase 3· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Jinming Yu
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Yu Jinming
Recruiting
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236· Phase 2· Fujian Cancer Hospital· Source
Contact: Qin Xu, Ph.D
Recruiting
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source
Contact: Shuqin Ni
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335· Phase 1· Shanghai Henlius Biotech· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Huihui Li, Site 1017
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Xiangjiao Meng
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706· Phase 3· Nuvation Bio Inc.· Source
Contact: Pingping Song, MD
Recruiting
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT07133750· Phase 2· Biotheus Inc.· Source
Contact: Changzheng Li
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Huihui Li, Doctor
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Recruiting
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
NCT07340424· Early phase 1· Xiaorong Sun· Source
Contact: Xiaorong Sun
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552· Phase 1· NextCure, Inc.· Source
Contact: Yan Zhang
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324· Phase 3· Nuvation Bio Inc.· Source
Contact: Linlin Wang, MD
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Yuanyuan Lv
Recruiting
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
NCT06617416· Phase 3· Akeso· Source
Contact: Jinming Yu, MD
Recruiting
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
NCT06819215· Phase 1/2· Zhejiang Yangli Pharmaceutical Technology Co., Ltd.· Source
Contact: Sun Yuping Chief physician, Doctor
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
NCT07135102· Phase 1· Xiaorong Sun· Source
Contact: Xiaorong Sun
Recruiting
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
NCT06434610· Phase 2· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source
Contact: Liang Chen
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994· Phase 3· InnoCare Pharma Inc.· Source
Contact: Zengjun Li
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190· Phase 2· Hansoh BioMedical R&D Company· Source
Contact: Lingying Wu, MD
Recruiting
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729· Phase 2· Hansoh BioMedical R&D Company· Source
Contact: Siwei Bao
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Recruiting
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07055841· Phase 2· Xiuping Ding· Source
Contact: Xiuping Ding, Dr
Recruiting
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
NCT05653453· Phase 3· Jiangsu Healthy Life Innovation Medical Technology Co., Ltd· Source
Contact: Fu
Active, not recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797· Phase 1/2· Eisai Inc.· Source